Clinical Trials Directory

Trials / Completed

CompletedNCT02892188

Physician-Pharmacist Collaboration for Osteoporotic Patient Follow-up

Assessment of the Follow-up of Osteoporotic Patients by a Physician-pharmacist Collaboration

Status
Completed
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
Centre Hospitalier Régional Metz-Thionville · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the follow-up of the osteoporotic patient by a physician-pharmacist collaboration.

Detailed description

Treatments allow decreasing the personal fracture risk from 48% to 85% provided that the treatment period is continued at least 3 to 5 years and that hygienic and dietary measures are applied: optimization of the dietary calcium intakes (much more efficient and less dangerous than the medicinal intakes), preservation of a physical activity, fall prevention. The ability of bisphosphonate for decreasing significantly the number of fractures was proved, but the lack of lasting adhesion (persistence) and of flanking measures leads to believe their efficiency may be enhanced: the hip-fracture rate decreases from 2.1% for the non-adherents to 1,3% for the patients with observance, which represents a one-half reduction. The cost of surgery for a femoral neck fracture is estimated at 8500 euros. So the prevention of only one femoral neck fracture entails a huge economy. However, 50% of women stop their treatment before a year and the implementation of hygienic and dietary measures leads to a lifestyle change, and faces long time ingrained habits. Only 42% of patients continue their treatment after two years, and only 16% after three years.

Conditions

Timeline

Start date
2013-01-01
Primary completion
2019-01-01
Completion
2019-02-01
First posted
2016-09-08
Last updated
2020-01-02

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02892188. Inclusion in this directory is not an endorsement.